CytoDyn (OTCQB:CYDY) announces that two COVID-19 patients in New York City were treated with leronlimab under an emergency IND granted by the FDA.
The company says leronlimab inhibits (binds to) a
protein on the surface of certain immune cells called Cysteine-Cysteine
Chemokine Receptor 5 (CCR5) which plays a key role in modulating immune
cell trafficking in sites of inflammation, so it may have potential to
treat COVID-19.
https://seekingalpha.com/news/3553237-fda-oks-emergency-ind-for-use-of-cytodyns-leronlimab-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.